Drugs / ALN-F1202
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06669234 | Mar 2025 → Jul 2026 overdue | — | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-F1202 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06669234 ↗ |
| Modality | Small interfering RNA (siRNA) | “an siRNA Against Factor XII” NCT06669234 ↗ |